Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2025 Multiple Myeloma Highlights
27 January 2026 | Virtual Webinar
Post-ASH 2025 Multiple Myeloma Highlights
Featuring presentations & discussions on selected myeloma abstracts from the 67th ASH Annual Meeting and Exposition
Tuesday 27 January | 08:00 – 10:00 CST/ 14:00 – 16:00 GMT/ 15:00 – 17:00 CET
Chair: Doris Hansen | Moderators: Nisha Joseph and Salomon Manier
Explore the presentations and panel discussions below:
Session 1: Updates in risk stratification and response-adapted management in myeloma and monoclonal gammopathies
Results of the PROMISE study from ~30,000 individuals screened for monoclonal gammopathies
Sabine Allam Dana-Farber Cancer Institute, Boston, MA, United States
Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous SCT
Luciano Costa UAB School of Medicine, Birmingham, AL, United States
Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression
Jonathan Kaufman Emory University School of Medicine, Atlanta, GA, United States
Session 2: Latest evidence with small molecule therapies and gene therapy
Update from the Phase II EMN26 trial: iberdomide maintenance after autologous SCT in newly diagnosed multiple myeloma
Niels van de Donk VU University Medical Center, Amsterdam, Netherlands
Preliminary results from inMMyCAR, the first-inhuman Phase I study of KLN-1010
Simon Harrison Peter MacCallum Cancer Centre, Melbourne, Australia
Panel Discussion
Session 3: Advances with CAR T-cell therapy in myeloma
Preliminary results from the Phase Ib/II DURGA-1 study: safety and efficacy of AZD0120 in R/R myeloma
Shambavi Richard Mount Sinai Medical Center, New York City, NY, United States
Phase II registrational study of anito-cel for patients with R/R myeloma: updated results from iMMagine-1
Krina Patel The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Enhancing the safety of cilta-cel in relapsed myeloma: identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality
Surbhi Sidana Stanford University, Stanford, CA, United States
Predictors of early relapse following cilta-cel: informing risk-adapted therapy in R/R myeloma
Doris Hansen Moffitt Cancer Center, Tampa, FL, United States
Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: a CIBMTR analysis
Hira Mian McMaster University, Hamilton, Canada
Panel Discussion
Session 4: Recent progress with T-cell engagers in treatment naïve and R/R myeloma
A Phase II study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: the IFM2021-01 TecLille trial, cohort A
Salomon Manier Lille Hospital University, Lille, France
Phase II study of cevostamab consolidation following BCMA CAR T-cell therapy: preliminary safety, efficacy, and correlative data from the “STEM” trial
Adam Cohen University of Pennsylvania, Philadelphia, PA, United States
Initial results of the first-in-human Phase I study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with R/R myeloma
Hang Quach The University of Melbourne, Melbourne, Australia
Safety and efficacy of linvoseltamab combined with daratumumab or isatuximab in patients with R/R myeloma: initial results from LINKER-MM2
Meletios Dimopoulos University of Athens School of Medicine, Athens, Greece
Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with R/R multiple myeloma
Amrita Krishnan City of Hope Medical Center, Duarte, CA, United States
Phase III study of teclistamab + daratumumab vs. investigator’s choice of daratumumab and dexamethasone with either pomalidomide or bortezomib in patients with R/R myeloma
Maria Victoria Mateos University Hospital of Salamanca, Salamanca, Spain
Panel Discussion
